- Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding
- The financing was provided exclusively by F-Prime Capital
- Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group
- As part of the strategic collaboration with Biogen, Atalanta will develop RNAi therapeutics for multiple targets
- The company will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products
- The strategic collaboration with Genentech involves the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases
